Sabby Management, LLC Contrafect Corp Transaction History

Sabby Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.79 - $4.45 $262,315 - $418,389	-94,020 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.26 - $3.84 $220,700 - $374,995	-97,655 Reduced 50.95%	94,020 $343,000
Q4 2021 Feb 14, 2022	BUY	$2.47 - $4.14 $62,985 - $105,569	25,500 Added 15.35%	191,675 $504,000
Q1 2021 May 17, 2021	BUY	$4.46 - $6.68 $741,140 - $1.11 Million	166,175 New	166,175 $798,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.